Advertisement

Taurine 8 pp 217-229 | Cite as

Effects of Taurine on Myocardial cGMP/cAMP Ratio, Antioxidant Ability, and Ultrastructure in Cardiac Hypertrophy Rats Induced by Isoproterenol

  • Qunhui Yang
  • Jiancheng Yang
  • Gaofeng Wu
  • Ying Feng
  • Qiufeng Lv
  • Shumei Lin
  • Jianmin HuEmail author
Conference paper
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 776)

Abstract

Taurine is the most abundant free amino acid in the human body and accounts for more than 50% of the total amino acid pool in the mammalian heart. To investigate the preventive effects of taurine on cardiac hypertrophy in rats, myocardial injury was established by hypodermic injection of isoprenaline (ISO) (10 mg/kg d) for 7 days. The preventive effects of taurine (100 mg/kg d, 200 mg/kg d, and 300 mg/kg d, i.p) on heart coefficient; ultrastructure of cardiac muscle; the levels of creatine kinase heart isoenzyme (CK-MB), cAMP, and cGMP; and antioxidant ability were investigated. The results showed that taurine could significantly prevent the increase of heart coefficient induced by ISO. Compared with the model group, 100 mg/kg and 200 mg/kg taurine significantly decrease the levels of cAMP and cGMP, while 300 mg/kg taurine could significantly decrease the levels of cAMP in myocardium, and all the three concentrations of taurine could significantly increase the ratio of cGMP/cAMP. The level of serum CK-MB was significantly increased by ISO; 200 mg/kg taurine could significantly decrease it, but 100 mg/kg and 300 mg/kg taurine had no significant effect. As for the antioxidant ability, ISO administration could significantly increase the myocardial level of MDA but had no significant effects on the myocardial levels of SOD, GSH, GSH-Px, and T-AOC. However, taurine administration could significantly decrease the myocardial level of MDA and increase the levels of GSH and T-AOC compared with the model group. The serum levels of SOD, GSH-Px, GSH, and T-AOC were significantly reduced by ISO administration, but the level of MDA showed no significant changes compared with the control group. Taurine administration could significantly increase the serum levels of SOD, GSH-Px, GSH, and T-AOC and decrease the level of MDA compared with the model group. All the results indicated that 200 mg/kg taurine had better effects. The ultrastructure of cardiomyocytes showed that taurine administration could significantly reverse the injury caused by ISO. In conclusion, the present study demonstrated that taurine could inhibit the injury induced by ISO by increasing myocardial negative inotropic effect and antioxidant ability, decreasing the hypertrophic response to isoproterenol and protecting the integrity of ­myocardial ultrastructure, decreasing myocardial leak of CK-MB.

Keywords

Model Group Cardiac Hypertrophy Antioxidant Ability Osmium Tetroxide Solution Taurine Administration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Abbreviations

ISO

Isoprenaline

CK-MB

Creatine kinase heart isoenzyme

cAMP

Cyclic adenosine monophosphate

cGMP

Cyclic guanosine monophosphate

MDA

Malondialdehyde

SOD

Superoxide dismutase

GSH

Reduced glutathione

GSH-Px

Glutathione peroxidase

T-AOC

Total antioxidation capacity

Notes

Acknowledgements

This study was supported by a grant from the Education Department of Liaoning Province, China.

References

  1. Adams JE 3rd, Abendschein DR, Jaffe AS (1993) Biochemical markers of myocardial injury. Is MB creatine kinase the choice for the 1990s? Circulation 88:750–763PubMedCrossRefGoogle Scholar
  2. Allard ML, Jeejeebhoy KN, Sole MJ (2006) The management of conditioned nutritional requirements in heart failure. Heart Fail Rev 1:75–82CrossRefGoogle Scholar
  3. Azuma M, Takahashi K, Fukuda T, Ohyabu Y, Yamamoto I, Kim S, Iwao H, Schaffer SW, Azuma J (2000) Taurine attenuates hypertrophy induced by angiotensin II in cultured neonatal rat cardiac myocytes. Eur J Pharmacol 403:181–188PubMedCrossRefGoogle Scholar
  4. Balligand JL (1999) Regulation of cardiac beta-adrenergic response by nitric oxide. Cardiovasc Res 43:607–620PubMedCrossRefGoogle Scholar
  5. Calderone A, Thaik CM, Takahashi N, Chang DF, Colucci WS (1998) Nitricoxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J Clin Invest 101:812–818PubMedCrossRefGoogle Scholar
  6. Chang L, Xu J, Yu F, Zhao J, Tang X, Tang C (2004) Taurine protected myocardial mitochondria injury induced by hyperhomocysteinemia in rats. Amino Acids 27:37–48PubMedCrossRefGoogle Scholar
  7. Chattopadhyay A, Biswas S, Bandyopadhyay D, Sarkar C, Datta AG (2003) Effect of isoproterenol on lipid peroxidation and antioxidant enzymes of myocardial tissue of mice and protection by quinidine. Mol Cell Biochem 245:43–49PubMedCrossRefGoogle Scholar
  8. Gan XL, Hei ZQ, Huang HQ, Chen LX, Li SR, Cai J (2006) Effect of Astragalus membranaceus injection on the activity of the intestinal mucosal mast cells after hemorrhagic shock-reperfusion in rats. Chin Med J 119:1892–1898PubMedGoogle Scholar
  9. Grazyna S, Hinrik S, Michael S, Yvonne BJ, James PM (1999) Altered phosphorylation of sarcoplasmic reticulum contributes to the diminished contractile response to isoproterenol in hypertrophied rat hearts. Eur J Physiol 439:1–10CrossRefGoogle Scholar
  10. Hamaguchi T, Azuma J, Schaffer S (1991) Interaction of taurine with methionine: inhibition of myocardial phospholipid methyltransferase. J Cardiovasc Pharmacol 18:224–230PubMedCrossRefGoogle Scholar
  11. Hare JM, Givertz MM, Creager MA, Colucci WS (1998) Increased sensitivity to nitric oxide synthase inhibition in patients with heart failure: potentiation of beta-adrenergic inotropic responsiveness. Circulation 97:161–166PubMedCrossRefGoogle Scholar
  12. Hill JA, Olson EN (2008) Cardiac plasticity. N Engl J Med 358:1370–1380PubMedCrossRefGoogle Scholar
  13. Huxtable R, Bressler R (1974) Taurine concentrations in congestive heart failure. Science 184:1187–1188PubMedCrossRefGoogle Scholar
  14. Ito T, Kimura Y, Uozumi Y, Takai M, Muraoka S, Matsuda T, Ueki K, Yoshiyama M, Ikawa M, Okabe M, Schaffer SW, Fujio Y, Azuma J (2008) Taurine depletion caused by knocking out the taurine transporter gene leads to cardiomyopathy with cardiac atrophy. J Mol Cell Cardiol 44:927–937PubMedCrossRefGoogle Scholar
  15. Itoh K, Minakawa M, Ono Y, Tsushima K, Fukui K, Fukuda I (2008) Role of oxidative stress in hypertrophied myoblasts stimulated by isoproterenol. Gen Thorac Cardiovasc Surg 56:170–176PubMedCrossRefGoogle Scholar
  16. Li Y, Arnold JMO, Pampillo M, Babwah AV, Peng TQ (2009) Taurine prevents cardiomyocyte death by inhibiting NADPH oxidase-mediated calpain activation. Free Radic Biol Med 46:51–61PubMedCrossRefGoogle Scholar
  17. Lombardini JB (1996) Taurine depletion in the intact animal stimulates in vitro phosphorylation of a 44-kDa protein present in the mitochondrial fraction of the rat heart. J Mol Cell Cardiol 28:1957–1961PubMedCrossRefGoogle Scholar
  18. Lorell BH, Carabello BA (2000) Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation 102:470–479PubMedCrossRefGoogle Scholar
  19. Moise NS, Pacioretty LM, Kallfelz FA, Stipanuk MH, King JM, Gilmour RF Jr (1991) Dietary taurine deficiency and dilated cardiomyopathy in the fox. Am Heart J 121:541–547PubMedCrossRefGoogle Scholar
  20. Oudit GY, Trivieri MG, Khaper N, Husain T, Wilson GJ, Liu P, Sole MJ, Backx PH (2004) Taurine supplementation reduces oxidative stress and improves cardiovascular function in an iron-overload murine model. Circulation 109:1877–1885PubMedCrossRefGoogle Scholar
  21. Pion PD, Kittleson MD, Rogers QR, Morris JG (1987) Myocardial failure in cat associated with low plasma taurine:a reversible cardiomyopathy. Science 237:764–768PubMedCrossRefGoogle Scholar
  22. Sahin MA, Yucel O, Guler A, Doganci S, Jahollari A, Cingoz F, Arslan S, Gamsizkan M, Yaman H, Demirkilic U (2011) Is there any cardioprotective role of Taurine during cold ischemic period following global myocardial ischemia? J Cardiothorac Surg 6:31–38PubMedCrossRefGoogle Scholar
  23. Sawyer DB, Siwik DA, Xiao L, Pimentel DR, Singh K, Colucci WS (2002) Role of oxidative stress in myocardial hypertrophy and failure. J Mol Cell Cardiol 34:379–388PubMedCrossRefGoogle Scholar
  24. Schaffer SW, Azuma J, Mozaffari M (2009) Role of antioxidant activity of taurine in diabetes. Can J Physiol Pharmacol 87:91–99PubMedCrossRefGoogle Scholar
  25. Shi YR, Bu DF, Qi YF, Gao L, Jiang HF, Pang YZ, Tang CS, Du JB (2002) Dysfunction of myocardial taurine transport and effect of taurine supplement in rats with isoproterenol-induced myocardial injury. Acta Pharmacol Sin 23(10):910–918PubMedGoogle Scholar
  26. Shiny KS, Kumar SHS, Farvin KHS, Anandan R, Devadasan K (2005) Protective effect of taurine on myocardial antioxidant status in isoprenaline-induced myocardial infarction in rats. J Pharm Pharmacol 57:1–5CrossRefGoogle Scholar
  27. Straznicka M, Gong G, Yan L, Scholz PM, Weiss HR (1999) Cyclic GMP protein kinase mediates negative metabolic and functional effects of cyclic GMP in control and hypertrophied rabbit cardiac myocytes. J Cardiovasc Pharmacol 34:229–236PubMedCrossRefGoogle Scholar
  28. Tardiff JC (2006) Cardiac hypertrophy: stressing out the heart. J Clin Invest 116(6):1467–1470PubMedCrossRefGoogle Scholar
  29. Vila-Petroff MG, Younes A, Egan J, Lakatta EG, Sollott SJ (1999) Activation of distinct cAMP-dependent and cGMP-dependent pathways by nitric oxide in cardiac myocytes. Circ Res 84:1020–1031PubMedCrossRefGoogle Scholar
  30. Wallimann T, Wyss M, Brdiczka D, Nicolay K, Eppenberger HM (1992) Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: the “phosphocreatine circuit” for cellular energy homeostasis. Biochem J 281:21–40PubMedGoogle Scholar
  31. Xu YJ, Arneja AS, Tappia PS, Dhalla NS (2008) The potential health benefits of taurine in cardiovascular disease. Exp Clin Cardiol 13(2):57–65PubMedGoogle Scholar
  32. Yamori Y, Liu L, Ikeda K, Miura A, Mizushima S, Miki T, Nara Y (2001) Distribution of twenty-four hour urinary taurine excretion and association with ischemic heart disease mortality in 24 populations of 16 countries: results from the WHOCARDIAC study. Hypertens Res 24(4):453PubMedCrossRefGoogle Scholar
  33. Yang JC, Wu GF, Feng Y, Lu QF, Lin SM, Hu JM (2010) Effects of taurine on male reproduction in rats of different ages. J Biomed Sci 17(Suppl 1):59–66CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Qunhui Yang
    • 1
  • Jiancheng Yang
    • 1
  • Gaofeng Wu
    • 1
  • Ying Feng
    • 1
  • Qiufeng Lv
    • 1
  • Shumei Lin
    • 1
  • Jianmin Hu
    • 1
    Email author
  1. 1.College of Animal Science and Veterinary MedicineShenyang Agricultural UniversityShenyangP.R. China

Personalised recommendations